MeiraGTx Holdings plc recently shared a corporate presentation outlining its late-stage clinical pipeline and end-to-end capabilities in genetic medicine technologies. The presentation highlights a broad program pipeline across neuro, salivary gland, and ophthalmology, with four pivotal stage programs focusing on Parkinson's disease, radiation-induced xerostomia, AIPL1 retinal dystrophy, and X-linked retinitis pigmentosa. MeiraGTx's preclinical pipeline includes diverse programs targeting ALS, obesity, Stargardt's, and wet AMD. The company emphasizes its in-house manufacturing capabilities, featuring two cGMP viral vector manufacturing facilities, in-house cGMP plasmid production, and a commercially-licensed QC facility. The presentation also discusses next-generation vector optimization and proprietary riboswitch technology for titratable control of gene expression. Expected near-term global BLA filings are projected for AIPL1 congenital blindness and RPGR X-linked RP in 2025, radiation-induced xerostomia in 2026, and Parkinson's disease in 2027. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.